Loading...
NPI 1699045674 · Reno, NV · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Md Spine Solutions LLC is a clinical medical laboratory provider located in Reno, Nevada. This profile covers 12 Medicare and 75 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Md Spine Solutions LLC |
| Address | 10715 Double R Blvd |
| City | Reno |
| State | NV |
| ZIP | 89521 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | January 6, 2012 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicaid | $26.3M |
| Medicare | $1.5M |
This entity is effectively Medicaid‑focused: lifetime Medicaid revenue is $26.3M compared with $1.5M in Medicare, indicating that Medicaid represents the dominant payer by scale for this provider. The disparity suggests the lab operates primarily as a high‑volume state Medicaid service rather than as a Medicare-centric supplier.
The provider’s product mix is concentrated in toxicology and laboratory diagnostics: top Medicare and Medicaid codes are dominated by definitive drug testing (G0481, G0482, G0483) and presumptive screening (80307), with additional molecular and infectious assays reported (examples include 81226 and 87798). This pattern is consistent with an operation that offers centralized toxicology services alongside a broader clinical lab portfolio that includes genetic and amplified‑probe infectious testing.
Medicare revenue is highly concentrated: the top three Medicare codes account for 75.4% of the provider’s total Medicare revenue, driven by G0481, G0482, and G0483. That concentration indicates most Medicare receipts come from multi‑panel definitive drug testing rather than a wide diversity of clinical services.
Medicaid revenue is also concentrated: the top three Medicaid codes account for 71.3% of this provider’s Medicaid revenue, primarily G0483, G0482, and 80307. Those three codes together generate the majority of Medicaid receipts and point to a business model centered on high‑volume toxicology and screening services for the state population.
This provider is a major competitive presence on key toxicology codes in both payers. On Medicare, G0481 ranks #15 of 1766 providers (99th percentile) and G0482 ranks #37 of 1618 (98th percentile), while 80307 ranks #62 of 4760 (99th percentile); on Medicaid in‑state comparisons, G0483, G0482, G0481 and 80307 all rank #1 of their peer groups (100th percentile) and are labeled as “extreme outlier” or “notably above typical” volumes. Those rankings indicate unusually high volume for drug testing relative to peers nationally (for Medicare) and especially within Nevada Medicaid.
The statistical labels attached in the data underline the provider’s outlier status in Medicaid: several top Medicaid codes are described as “extreme outlier, far above typical state volume” or “extreme outlier, far above typical state volume for this code,” reinforcing that G0483, G0482 and 80307 performance is atypically large within the state. For Medicare, G0481 is described as “notably above typical national volume,” while other Medicare toxicology codes are characterized as typical or unremarkable, signaling a selective national strength.
The provider also bills for higher‑complexity molecular and genetic tests alongside high-volume toxicology. Examples include Medicare billing for 81226 (73 claims, $442 avg paid/claim, $32.3K revenue) and Medicaid billing for 81162 (54 claims, $1093 avg paid/claim, $59K revenue), plus a range of amplified‑probe infectious codes such as 87798 (50.4K claims, $51 avg paid/claim, $2.6M revenue on Medicaid). This mix shows capability to perform both routine high-throughput screens and specialized molecular assays, which can support diversified contract opportunities despite toxicology concentration.
The provider has an established tenure in the national NPI registry (NPI enumerated 2012-01-06 (~14 years ago)), suggesting a sustained operating history. Taken together with the concentrated Medicaid scale and statewide dominance on multiple laboratory codes, the profile is consistent with a long‑standing, Medicaid‑oriented lab operation with significant market share in toxicology services within Nevada.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
12 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 3,450 | $150 | $528.5K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 1,770 | $190 | $343K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 1,060 | $240 | $255.2K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 3,560 | $60 | $217.4K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 840 | $110 | $94K |
| 81226 | The lab analyst performs the technical lab test to detect the presence of common changes in the gene for cytochrome P450, family 2, subfamily D, polypeptide 6, also known as CYP2D6. | 70 | $440 | $32.3K |
| 81225 | The lab analyst performs the technical lab test to detect the presence of common changes in the gene for cytochrome P450, family 2, subfamily C, polypeptide 19, also known as CYP2C19. | 30 | $290 | $7.7K |
| 81227 | The lab analyst performs the technical lab test to detect the presence of common changes in the gene for cytochrome P450, family 2, subfamily C, polypeptide 9, also known as CYP2C9. | 30 | $170 | $4.3K |
| 81328 | The lab analyst performs the technical lab test to detect the presence of specific changes in the solute carrier organic anion transporter family, member 1B1 (SLCO1B) gene for common variants, such… | 20 | $170 | $3.8K |
| 81335 | The lab analyst performs the technical lab test to detect the presence of specific changes in the thiopurine S–methyltransferase (TPMT) gene for common variants, such as *2, *3. | 20 | $170 | $3.1K |
Showing 1–10 of 12
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 12 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
75 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 149,760 | $70 | $10.2M |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 46,790 | $90 | $4.3M |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 160,010 | $30 | $4M |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 50,430 | $50 | $2.6M |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 39,420 | $60 | $2.4M |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 17,190 | $60 | $1M |
| 87481 | The lab analyst performs a test for Candida species using amplified nucleic acid probe technique. | 16,080 | $10 | $225.1K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 6,580 | $30 | $223.6K |
| 87653 | The lab analyst performs a test for Streptococcus, group B, using amplified nucleic acid probe technique. The amplified probe provides a rapid means to assess colonization by Streptococcus, group B,… | 16,210 | $10 | $194.5K |
| 87500 | The lab analyst performs a test for vancomycin resistance in an infectious organism’s nucleic acid using amplified probe technique. VRE, vancomycin resistant enterococcus, is the most common organism… | 9,870 | $10 | $118.4K |
Showing 1–10 of 75
How this provider's Medicaid billing volume and revenue compare to other Nevada providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Nevada median
75 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 1 | 40 | 530 | $70 | $561K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 6 | 60 | 680 | $60 | $364.3K |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 1 | 30 | 290 | $60 | $260.3K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 1 | 30 | 750 | $90 | $252.3K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 1 | 150 | 1,440 | $20 | $193.7K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 3 | 50 | 910 | $40 | $164K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 1 | 40 | 310 | $50 | $129.2K |
| 87150 | The lab analyst performs an analysis using amplified DNA or RNA probe technique on a previously isolated and identified organism to categorize the organism more specifically, such as to the taxonomic… | 6 | 10 | 580 | $90 | $85.4K |
| 87801 | The lab analyst performs a test for multiple infectious agents using amplified nucleic acid probe technique. | 7 | 10 | 300 | $20 | $76.9K |
| 87491 | The lab analyst performs a test for Chlamydia trachomatis using amplified nucleic acid probe technique. | 8 | 90 | 250 | $10 | $64.7K |
Showing 1–10 of 75
Other providers in the same ZIP code as Md Spine Solutions LLC, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.